Alterity Therapeutics (ATHE) Stock Price, News & Analysis

Company Overview

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Key Stats

• Today's Range: $3.31 to $3.45
• 50-Day Range: $2.54 to $4.17
• 52-Week Range: $1.00 to $5.87
• Volume: 12,572 shs
• Average Volume: 137,633 shs
• Market Capitalization: $30.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Moderate Buy

Alterity Therapeutics Stock Analysis - MarketRank™

Alterity Therapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 594th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alterity Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Alterity Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Alterity Therapeutics has a P/B Ratio of 3.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.39% of the float of Alterity Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Alterity Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alterity Therapeutics has recently increased by 32.71%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alterity Therapeutics does not currently pay a dividend.

Dividend Growth

Alterity Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.39% of the float of Alterity Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Alterity Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alterity Therapeutics has recently increased by 32.71%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.22

News Sentiment

Alterity Therapeutics has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Alterity Therapeutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alterity Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

38.80% of the stock of Alterity Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 2.14% of the stock of Alterity Therapeutics is held by institutions.

ATHE Stock Analysis - Frequently Asked Questions

How have ATHE shares performed this year?

Alterity Therapeutics' stock was trading at $3.31 at the beginning of the year. Since then, ATHE shares have increased by 3.1% and is now trading at $3.4110.
View the best growth stocks for 2025 here.

When did Alterity Therapeutics' stock split?

Alterity Therapeutics shares reverse split before market open on Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Alterity Therapeutics?

Shares of ATHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Alterity Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alterity Therapeutics investors own include NVIDIA (NVDA), GE Aerospace (GE), Broadcom (AVGO), Meta Platforms (META), Dorian LPG (LPG), CymaBay Therapeutics (CBAY) and

Company Calendar

• Today: 5/01/2025
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ATHE
• CIK: 1131343
• Web: www.alteritytherapeutics.com
• Phone: (139) 349-4906
• Fax: 61-3-9348-0377
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $12.00
• High Stock Price Target: $12.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +251.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.54
• Quick Ratio: 3.54

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.04 per share
• Price / Book: 3.28

Miscellaneous

• Outstanding Shares: 8,867,000
• Free Float: 5,350,000
• Market Cap: $30.25 million
• Optionable: Not Optionable
• Beta: 0.71